Showing results (361-370 of 434) with videos related to

Sort By:
Pageof 44
The Pediatric Infectious Disease Journal|May 11, 2026
Long COVID-19 in Hospitalized and Ambulatory Children in JamaicaSamantha Ann-Patrice Mosha Miller, Mark Daniel Hicar, Crista-Lee Shahine Berry, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 30, 2007
Buprenorphine assay and plasma concentration monitoring in HIV-infected substance usersRobin DiFrancesco, Margaret A Fischl, Julie Donnelly, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 31, 2010
Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavirRobert Douglas Bruce, Frederick L Altice, David E Moody, et al.
Pharmaceutical Research|November 10, 2018
Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and VaccinesRaymonde B Bekale, Su-Mari Du Plessis, Nai-Jen Hsu, et al.
Emerging Infectious Diseases|March 27, 2001
Active bacterial core surveillance of the emerging infections program networkA Schuchat, T Hilger, E Zell, et al.
The New England Journal of Medicine|May 10, 1990
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trialJ S Lambert, M Seidlin, R C Reichman, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|December 31, 2015
A Randomized Controlled Trial of Mentoring Interventions for Underrepresented MinoritiesVivian Lewis, Camille A Martina, Michael P McDermott, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2014
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202Charles S Venuto, Katie Mollan, Qing Ma, et al.
Journal of Neurovirology|June 6, 2013
Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patientsQing Ma, Harris A Gelbard, Sanjay B Maggirwar, et al.
Pageof 44